HSBC says this biopharma company can jump 25% despite 'patent cliff'

  • 📰 CNBC
  • ⏱ Reading Time:
  • 5 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 5%
  • Publisher: 72%

México Noticias Noticias

México Últimas Noticias,México Titulares

HSBC initiated coverage on the drug treatment developer with a buy rating.

Its price target of $320 suggests shares could rally 25% from Tuesday's close. "Amgen is a best-in-class operator with high margins and a strong history of protecting its assets. While some very old products are finally facing patent cliffs it will likely be gradual and a broadened portfolio allows for continued growth," analyst Morten Herholdt wrote in a Wednesday note.

mountain AMGN in 2023 — CNBC's Michael Bloom contributed to this report.

 

Gracias por tu comentario. Tu comentario será publicado después de ser revisado.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

 /  🏆 12. in MX

México Últimas Noticias, México Titulares